[
  {
    "objectID": "quarto/index.html",
    "href": "quarto/index.html",
    "title": "The Role of Chronic Kidney Disease in Modulating PCI Outcomes in Myocardial Infarction: Insights from the National Inpatient Sample",
    "section": "",
    "text": "Reference Papers:\n\nHolzmann et al. (2020)\n\nStudy Objective: Investigate the impact of chronic kidney disease (CKD) on percutaneous coronary intervention (PCI) outcomes in patients admitted with acute myocardial infarction (AMI) across U.S. hospitals from 2018 to 2020. The study evaluates whether outcomes vary based on CKD severity (Stage 1 to 5 or end-stage kidney disease [ESKD]), adjusting for demographic, clinical, and hospital factors.\nData Source: Cross-sectional analysis using the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all inpatient admissions with:\n\nA principal diagnosis of acute myocardial infarction (AMI) (ICD-10 DX codes I21.xx).\nDocumented chronic kidney disease (CKD), categorized by severity (Stages 1–5 or ESKD, ICD-10 DX codes N18[1-6].xx).\nUnderwent percutaneous coronary intervention (PCI) during hospitalization.\n\nPrimary Outcomes:\n\nIn-hospital Mortality (binary: yes/no).\nLength of Stay (LOS) (continuous: days).\nInflation-Adjusted Total Charge ($, inflation adjusted to 2020 dollars using Consumer Price Index [CPI] data from the U.S. Bureau of Labor Statistics).\n\nStatistical Analysis: Multivariable logistic and linear regression analyses were conducted to evaluate the independent association of CKD severity with each outcome, adjusting for:\n\nDemographics and Clinical Factors: Age, sex, race/ethnicity, acute MI type (STEMI, NSTEMI, or other MI), insurance payer, income quartile, Charlson Comorbidity Index, atrial fibrillation, cerebrovascular disease, heart failure, diabetes mellitus, hyperlipidemia, hypertension, peripheral vascular disease, prior MI, and prior PCI.\nHospital Factors: Region, bed size, and location/teaching status.\n\nSoftware: All analyses were conducted using the R Statistical Language (Version 4.4.2; R Foundation for Statistical Computing, Vienna, Austria), employing survey-weighted methods to account for the complex sampling design of the NIS."
  },
  {
    "objectID": "quarto/index.html#preamble",
    "href": "quarto/index.html#preamble",
    "title": "The Role of Chronic Kidney Disease in Modulating PCI Outcomes in Myocardial Infarction: Insights from the National Inpatient Sample",
    "section": "",
    "text": "Reference Papers:\n\nHolzmann et al. (2020)\n\nStudy Objective: Investigate the impact of chronic kidney disease (CKD) on percutaneous coronary intervention (PCI) outcomes in patients admitted with acute myocardial infarction (AMI) across U.S. hospitals from 2018 to 2020. The study evaluates whether outcomes vary based on CKD severity (Stage 1 to 5 or end-stage kidney disease [ESKD]), adjusting for demographic, clinical, and hospital factors.\nData Source: Cross-sectional analysis using the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all inpatient admissions with:\n\nA principal diagnosis of acute myocardial infarction (AMI) (ICD-10 DX codes I21.xx).\nDocumented chronic kidney disease (CKD), categorized by severity (Stages 1–5 or ESKD, ICD-10 DX codes N18[1-6].xx).\nUnderwent percutaneous coronary intervention (PCI) during hospitalization.\n\nPrimary Outcomes:\n\nIn-hospital Mortality (binary: yes/no).\nLength of Stay (LOS) (continuous: days).\nInflation-Adjusted Total Charge ($, inflation adjusted to 2020 dollars using Consumer Price Index [CPI] data from the U.S. Bureau of Labor Statistics).\n\nStatistical Analysis: Multivariable logistic and linear regression analyses were conducted to evaluate the independent association of CKD severity with each outcome, adjusting for:\n\nDemographics and Clinical Factors: Age, sex, race/ethnicity, acute MI type (STEMI, NSTEMI, or other MI), insurance payer, income quartile, Charlson Comorbidity Index, atrial fibrillation, cerebrovascular disease, heart failure, diabetes mellitus, hyperlipidemia, hypertension, peripheral vascular disease, prior MI, and prior PCI.\nHospital Factors: Region, bed size, and location/teaching status.\n\nSoftware: All analyses were conducted using the R Statistical Language (Version 4.4.2; R Foundation for Statistical Computing, Vienna, Austria), employing survey-weighted methods to account for the complex sampling design of the NIS."
  },
  {
    "objectID": "quarto/index.html#baseline-table",
    "href": "quarto/index.html#baseline-table",
    "title": "The Role of Chronic Kidney Disease in Modulating PCI Outcomes in Myocardial Infarction: Insights from the National Inpatient Sample",
    "section": "Baseline Table:",
    "text": "Baseline Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall\nN = 163,745\n1\nCKD, Stage 3\nN = 93,830\n1\nCKD, Stage 1\nN = 1,450\n1\nCKD, Stage 2\nN = 14,005\n1\nCKD, Stage 4\nN = 17,150\n1\nCKD, Stage 5\nN = 1,755\n1\nESKD\nN = 35,555\n1\np-value\n2\n\n\n\n\nAge, y\n70 (11)\n72 (11)\n65 (12)\n68 (11)\n72 (11)\n69 (12)\n65 (11)\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Female\n56,805 (35%)\n32,120 (34%)\n390 (27%)\n3,455 (25%)\n6,670 (39%)\n710 (40%)\n13,460 (38%)\n\n\n\n\n    Male\n106,935 (65%)\n61,710 (66%)\n1,060 (73%)\n10,545 (75%)\n10,480 (61%)\n1,045 (60%)\n22,095 (62%)\n\n\n\n\nRace\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    White\n110,915 (69%)\n70,045 (77%)\n1,005 (70%)\n9,855 (72%)\n12,105 (73%)\n1,005 (59%)\n16,900 (49%)\n\n\n\n\n    Asian or Pacific Islander\n6,110 (3.8%)\n2,510 (2.7%)\n80 (5.6%)\n400 (2.9%)\n715 (4.3%)\n115 (6.7%)\n2,290 (6.6%)\n\n\n\n\n    Black\n21,925 (14%)\n9,740 (11%)\n150 (10%)\n1,850 (14%)\n1,885 (11%)\n310 (18%)\n7,990 (23%)\n\n\n\n\n    Hispanic\n15,060 (9.4%)\n6,455 (7.1%)\n120 (8.4%)\n1,090 (8.0%)\n1,350 (8.1%)\n230 (13%)\n5,815 (17%)\n\n\n\n\n    Native American\n1,300 (0.8%)\n515 (0.6%)\n15 (1.0%)\n85 (0.6%)\n160 (1.0%)\n5 (0.3%)\n520 (1.5%)\n\n\n\n\n    Other\n4,450 (2.8%)\n2,295 (2.5%)\n60 (4.2%)\n360 (2.6%)\n460 (2.8%)\n50 (2.9%)\n1,225 (3.5%)\n\n\n\n\nMI type\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Non-ST-elevation MI\n124,740 (76%)\n70,025 (75%)\n965 (67%)\n10,125 (72%)\n12,900 (75%)\n1,200 (68%)\n29,525 (83%)\n\n\n\n\n    Other MI\n2,140 (1.3%)\n1,100 (1.2%)\n15 (1.0%)\n145 (1.0%)\n180 (1.0%)\n35 (2.0%)\n665 (1.9%)\n\n\n\n\n    ST-elevation MI\n36,865 (23%)\n22,705 (24%)\n470 (32%)\n3,735 (27%)\n4,070 (24%)\n520 (30%)\n5,365 (15%)\n\n\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Medicaid\n10,560 (6.5%)\n5,175 (5.5%)\n100 (6.9%)\n1,165 (8.3%)\n1,070 (6.2%)\n160 (9.2%)\n2,890 (8.1%)\n\n\n\n\n    Medicare\n121,290 (74%)\n69,640 (74%)\n805 (56%)\n8,755 (63%)\n13,150 (77%)\n1,225 (70%)\n27,715 (78%)\n\n\n\n\n    Other\n7,365 (4.5%)\n4,575 (4.9%)\n80 (5.5%)\n865 (6.2%)\n640 (3.7%)\n110 (6.3%)\n1,095 (3.1%)\n\n\n\n\n    Private\n24,355 (15%)\n14,330 (15%)\n465 (32%)\n3,200 (23%)\n2,275 (13%)\n250 (14%)\n3,835 (11%)\n\n\n\n\nResidential income\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    $1 - $51,999\n49,360 (31%)\n26,905 (29%)\n330 (23%)\n4,105 (30%)\n5,035 (30%)\n525 (31%)\n12,460 (36%)\n\n\n\n\n    $52,000 - $65,999\n44,755 (28%)\n26,260 (28%)\n350 (24%)\n4,000 (29%)\n4,755 (28%)\n410 (24%)\n8,980 (26%)\n\n\n\n\n    $66,000 - $87,999\n38,845 (24%)\n22,820 (25%)\n340 (24%)\n3,235 (23%)\n4,070 (24%)\n430 (25%)\n7,950 (23%)\n\n\n\n\n    $88,000 or more\n28,370 (18%)\n16,485 (18%)\n410 (29%)\n2,500 (18%)\n3,010 (18%)\n350 (20%)\n5,615 (16%)\n\n\n\n\nHospital region\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Midwest\n42,165 (26%)\n26,325 (28%)\n295 (20%)\n3,925 (28%)\n4,360 (25%)\n325 (19%)\n6,935 (20%)\n\n\n\n\n    Northeast\n24,115 (15%)\n13,390 (14%)\n295 (20%)\n2,120 (15%)\n2,695 (16%)\n265 (15%)\n5,350 (15%)\n\n\n\n\n    South\n65,175 (40%)\n36,455 (39%)\n500 (34%)\n5,470 (39%)\n6,875 (40%)\n750 (43%)\n15,125 (43%)\n\n\n\n\n    West\n32,290 (20%)\n17,660 (19%)\n360 (25%)\n2,490 (18%)\n3,220 (19%)\n415 (24%)\n8,145 (23%)\n\n\n\n\nHospital bedsize\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n0.007\n\n\n    Large\n90,350 (55%)\n51,165 (55%)\n960 (66%)\n8,135 (58%)\n9,495 (55%)\n1,010 (58%)\n19,585 (55%)\n\n\n\n\n    Medium\n47,560 (29%)\n27,660 (29%)\n325 (22%)\n3,735 (27%)\n4,900 (29%)\n525 (30%)\n10,415 (29%)\n\n\n\n\n    Small\n25,835 (16%)\n15,005 (16%)\n165 (11%)\n2,135 (15%)\n2,755 (16%)\n220 (13%)\n5,555 (16%)\n\n\n\n\nHospital location/teaching status\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Rural\n8,290 (5.1%)\n5,420 (5.8%)\n60 (4.1%)\n640 (4.6%)\n830 (4.8%)\n90 (5.1%)\n1,250 (3.5%)\n\n\n\n\n    Urban, non-teaching\n27,100 (17%)\n15,940 (17%)\n245 (17%)\n2,160 (15%)\n2,880 (17%)\n250 (14%)\n5,625 (16%)\n\n\n\n\n    Urban, teaching\n128,355 (78%)\n72,470 (77%)\n1,145 (79%)\n11,205 (80%)\n13,440 (78%)\n1,415 (81%)\n28,680 (81%)\n\n\n\n\nCharlson comorbidity index\n5.63 (1.52)\n5.53 (1.56)\n5.28 (1.51)\n5.24 (1.58)\n5.90 (1.48)\n5.79 (1.37)\n5.95 (1.36)\n&lt;0.001\n\n\nAtrial fibrillation\n40,010 (24%)\n23,425 (25%)\n300 (21%)\n3,135 (22%)\n4,215 (25%)\n355 (20%)\n8,580 (24%)\n0.010\n\n\nCerebrovascular disease\n15,985 (9.8%)\n9,095 (9.7%)\n120 (8.3%)\n1,200 (8.6%)\n1,815 (11%)\n175 (10.0%)\n3,580 (10%)\n0.12\n\n\nHeart failure\n101,055 (62%)\n54,085 (58%)\n630 (43%)\n7,145 (51%)\n12,175 (71%)\n1,290 (74%)\n25,730 (72%)\n&lt;0.001\n\n\nDiabetes mellitus\n105,820 (65%)\n56,520 (60%)\n885 (61%)\n7,665 (55%)\n12,060 (70%)\n1,250 (71%)\n27,440 (77%)\n&lt;0.001\n\n\nHyperlipidemia\n125,005 (76%)\n74,250 (79%)\n1,170 (81%)\n11,295 (81%)\n12,730 (74%)\n1,185 (68%)\n24,375 (69%)\n&lt;0.001\n\n\nHypertension\n156,855 (96%)\n89,600 (95%)\n1,305 (90%)\n13,025 (93%)\n16,605 (97%)\n1,690 (96%)\n34,630 (97%)\n&lt;0.001\n\n\nPeripheral vascular disease\n26,000 (16%)\n15,295 (16%)\n205 (14%)\n1,945 (14%)\n2,920 (17%)\n205 (12%)\n5,430 (15%)\n&lt;0.001\n\n\nPrior MI\n33,290 (20%)\n19,125 (20%)\n240 (17%)\n2,725 (19%)\n3,350 (20%)\n300 (17%)\n7,550 (21%)\n0.056\n\n\nPrior PCI\n31,555 (19%)\n18,215 (19%)\n175 (12%)\n2,500 (18%)\n3,160 (18%)\n225 (13%)\n7,280 (20%)\n&lt;0.001\n\n\n\n1\nMean (SD); n (%)\n\n\n2\nDesign-based KruskalWallis test; Pearson’s X^2: Rao & Scott adjustment"
  },
  {
    "objectID": "quarto/index.html#outcomes-table",
    "href": "quarto/index.html#outcomes-table",
    "title": "The Role of Chronic Kidney Disease in Modulating PCI Outcomes in Myocardial Infarction: Insights from the National Inpatient Sample",
    "section": "Outcomes Table:",
    "text": "Outcomes Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall\nN = 163,745\n1\nCKD, Stage 3\nN = 93,830\n1\nCKD, Stage 1\nN = 1,450\n1\nCKD, Stage 2\nN = 14,005\n1\nCKD, Stage 4\nN = 17,150\n1\nCKD, Stage 5\nN = 1,755\n1\nESKD\nN = 35,555\n1\np-value\n2\n\n\n\n\nDied during hospitalization\n8,745 (5.3%)\n4,180 (4.5%)\n25 (1.7%)\n475 (3.4%)\n1,245 (7.3%)\n205 (12%)\n2,615 (7.4%)\n&lt;0.001\n\n\nLength of stay (days)\n5 (2, 10)\n4 (2, 9)\n4 (2, 9)\n4 (2, 8)\n6 (3, 12)\n6 (3, 13)\n6 (3, 11)\n&lt;0.001\n\n\nInflation-adjusted total charge ($)\n125,010 (79,189, 214,228)\n116,113 (75,122, 195,922)\n124,287 (79,120, 208,851)\n116,983 (75,514, 190,931)\n134,431 (82,327, 231,382)\n152,317 (87,110, 267,778)\n151,483 (92,825, 267,852)\n&lt;0.001\n\n\n\n1\nn (%); Median (Q1, Q3)\n\n\n2\nPearson’s X^2: Rao & Scott adjustment; Design-based KruskalWallis test"
  },
  {
    "objectID": "quarto/index.html#multivariable-logistic-regression",
    "href": "quarto/index.html#multivariable-logistic-regression",
    "title": "The Role of Chronic Kidney Disease in Modulating PCI Outcomes in Myocardial Infarction: Insights from the National Inpatient Sample",
    "section": "Multivariable Logistic Regression:",
    "text": "Multivariable Logistic Regression:\n\nIn-Hospital Mortality:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR\n1\n95% CI\n1\np-value\n\n\n\n\nCKD type\n\n\n\n\n\n\n\n\n    CKD, Stage 3\n—\n—\n\n\n\n\n    CKD, Stage 1\n0.37\n0.14, 1.00\n0.050\n\n\n    CKD, Stage 2\n0.84\n0.67, 1.06\n0.14\n\n\n    CKD, Stage 4\n1.50\n1.28, 1.75\n&lt;0.001\n\n\n    CKD, Stage 5\n2.45\n1.71, 3.51\n&lt;0.001\n\n\n    ESKD\n2.02\n1.78, 2.30\n&lt;0.001\n\n\nAge, y\n1.03\n1.02, 1.04\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n0.88\n0.79, 0.97\n0.015\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n1.21\n0.94, 1.55\n0.14\n\n\n    Black\n0.83\n0.70, 0.98\n0.026\n\n\n    Hispanic\n0.91\n0.76, 1.10\n0.3\n\n\n    Native American\n1.85\n1.20, 2.83\n0.005\n\n\n    Other\n0.97\n0.72, 1.31\n0.9\n\n\nMI type\n\n\n\n\n\n\n\n\n    Non-ST-elevation MI\n—\n—\n\n\n\n\n    Other MI\n1.12\n0.72, 1.76\n0.6\n\n\n    ST-elevation MI\n3.15\n2.83, 3.50\n&lt;0.001\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Medicaid\n—\n—\n\n\n\n\n    Medicare\n0.93\n0.73, 1.19\n0.6\n\n\n    Other\n0.87\n0.61, 1.24\n0.4\n\n\n    Private\n0.93\n0.71, 1.21\n0.6\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n0.91\n0.79, 1.05\n0.2\n\n\n    $66,000 - $87,999\n0.89\n0.77, 1.03\n0.12\n\n\n    $88,000 or more\n0.98\n0.83, 1.15\n0.8\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n0.81\n0.68, 0.96\n0.015\n\n\n    South\n1.03\n0.90, 1.18\n0.6\n\n\n    West\n1.12\n0.95, 1.31\n0.2\n\n\nHospital bedsize\n\n\n\n\n\n\n\n\n    Large\n—\n—\n\n\n\n\n    Medium\n1.01\n0.90, 1.14\n0.8\n\n\n    Small\n1.02\n0.88, 1.18\n0.8\n\n\nHospital location/teaching status\n\n\n\n\n\n\n\n\n    Rural\n—\n—\n\n\n\n\n    Urban, non-teaching\n1.27\n0.94, 1.72\n0.12\n\n\n    Urban, teaching\n1.46\n1.10, 1.94\n0.008\n\n\nCharlson comorbidity index\n1.07\n1.02, 1.12\n0.004\n\n\nAtrial fibrillation\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.26\n1.12, 1.41\n&lt;0.001\n\n\nCerebrovascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.48\n1.26, 1.74\n&lt;0.001\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.98\n1.74, 2.27\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.91\n0.79, 1.05\n0.2\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.51\n0.46, 0.57\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.82\n0.65, 1.03\n0.084\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.18\n1.02, 1.36\n0.022\n\n\nPrior MI\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.74\n0.64, 0.86\n&lt;0.001\n\n\nPrior PCI\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.67\n0.57, 0.78\n&lt;0.001\n\n\n\n1\nOR = Odds Ratio, CI = Confidence Interval"
  },
  {
    "objectID": "quarto/index.html#multivariable-linear-regression",
    "href": "quarto/index.html#multivariable-linear-regression",
    "title": "The Role of Chronic Kidney Disease in Modulating PCI Outcomes in Myocardial Infarction: Insights from the National Inpatient Sample",
    "section": "Multivariable Linear Regression:",
    "text": "Multivariable Linear Regression:\n\nLength of Stay:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI\n1\np-value\n\n\n\n\nCKD type\n\n\n\n\n\n\n\n\n    CKD, Stage 3\n—\n—\n\n\n\n\n    CKD, Stage 1\n-0.19\n-0.87, 0.48\n0.6\n\n\n    CKD, Stage 2\n-0.39\n-0.62, -0.15\n0.001\n\n\n    CKD, Stage 4\n1.4\n1.1, 1.7\n&lt;0.001\n\n\n    CKD, Stage 5\n1.9\n1.0, 2.7\n&lt;0.001\n\n\n    ESKD\n1.4\n1.1, 1.7\n&lt;0.001\n\n\nAge, y\n-0.01\n-0.01, 0.00\n0.2\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n-0.01\n-0.19, 0.17\n0.9\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n0.94\n0.35, 1.5\n0.002\n\n\n    Black\n0.01\n-0.28, 0.29\n&gt;0.9\n\n\n    Hispanic\n0.84\n0.49, 1.2\n&lt;0.001\n\n\n    Native American\n0.33\n-0.77, 1.4\n0.6\n\n\n    Other\n0.62\n-0.05, 1.3\n0.071\n\n\nMI type\n\n\n\n\n\n\n\n\n    Non-ST-elevation MI\n—\n—\n\n\n\n\n    Other MI\n0.23\n-0.45, 0.91\n0.5\n\n\n    ST-elevation MI\n-1.1\n-1.3, -0.93\n&lt;0.001\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Medicaid\n—\n—\n\n\n\n\n    Medicare\n-1.4\n-1.9, -0.84\n&lt;0.001\n\n\n    Other\n-0.77\n-1.4, -0.14\n0.017\n\n\n    Private\n-0.80\n-1.3, -0.28\n0.003\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n-0.08\n-0.30, 0.14\n0.5\n\n\n    $66,000 - $87,999\n0.02\n-0.22, 0.27\n0.9\n\n\n    $88,000 or more\n-0.07\n-0.34, 0.20\n0.6\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n1.2\n0.79, 1.6\n&lt;0.001\n\n\n    South\n0.60\n0.37, 0.83\n&lt;0.001\n\n\n    West\n-0.25\n-0.53, 0.03\n0.079\n\n\nHospital bedsize\n\n\n\n\n\n\n\n\n    Large\n—\n—\n\n\n\n\n    Medium\n-0.98\n-1.2, -0.75\n&lt;0.001\n\n\n    Small\n-1.6\n-1.8, -1.3\n&lt;0.001\n\n\nHospital location/teaching status\n\n\n\n\n\n\n\n\n    Rural\n—\n—\n\n\n\n\n    Urban, non-teaching\n0.71\n0.27, 1.1\n0.001\n\n\n    Urban, teaching\n1.8\n1.4, 2.2\n&lt;0.001\n\n\nCharlson comorbidity index\n0.28\n0.19, 0.36\n&lt;0.001\n\n\nAtrial fibrillation\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.1\n1.9, 2.3\n&lt;0.001\n\n\nCerebrovascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.6\n2.2, 3.0\n&lt;0.001\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.6\n2.4, 2.8\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.05\n-0.29, 0.20\n0.7\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1.8\n-2.1, -1.6\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.72\n-1.3, -0.10\n0.024\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.27\n-0.51, -0.03\n0.029\n\n\nPrior MI\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1.2\n-1.4, -1.1\n&lt;0.001\n\n\nPrior PCI\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1.5\n-1.7, -1.4\n&lt;0.001\n\n\n\n1\nCI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nInflation Adjusted Total Charge:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI\n1\np-value\n\n\n\n\nCKD type\n\n\n\n\n\n\n\n\n    CKD, Stage 3\n—\n—\n\n\n\n\n    CKD, Stage 1\n58\n-20,254, 20,369\n&gt;0.9\n\n\n    CKD, Stage 2\n-1,640\n-7,870, 4,589\n0.6\n\n\n    CKD, Stage 4\n17,032\n10,318, 23,745\n&lt;0.001\n\n\n    CKD, Stage 5\n29,730\n7,654, 51,805\n0.008\n\n\n    ESKD\n44,883\n36,413, 53,352\n&lt;0.001\n\n\nAge, y\n-425\n-648, -203\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n7,412\n2,407, 12,416\n0.004\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n29,245\n10,246, 48,244\n0.003\n\n\n    Black\n-5,284\n-12,736, 2,168\n0.2\n\n\n    Hispanic\n39,494\n28,789, 50,198\n&lt;0.001\n\n\n    Native American\n-15,435\n-39,321, 8,452\n0.2\n\n\n    Other\n40,023\n15,663, 64,384\n0.001\n\n\nMI type\n\n\n\n\n\n\n\n\n    Non-ST-elevation MI\n—\n—\n\n\n\n\n    Other MI\n-7,727\n-26,362, 10,909\n0.4\n\n\n    ST-elevation MI\n-4,748\n-10,506, 1,009\n0.11\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Medicaid\n—\n—\n\n\n\n\n    Medicare\n-10,882\n-20,851, -913\n0.032\n\n\n    Other\n-3,660\n-16,913, 9,594\n0.6\n\n\n    Private\n320\n-12,168, 12,808\n&gt;0.9\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n260\n-5,879, 6,399\n&gt;0.9\n\n\n    $66,000 - $87,999\n4,323\n-2,313, 10,960\n0.2\n\n\n    $88,000 or more\n6,539\n-2,327, 15,405\n0.15\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n33,001\n22,536, 43,467\n&lt;0.001\n\n\n    South\n39,152\n32,423, 45,881\n&lt;0.001\n\n\n    West\n84,287\n71,553, 97,021\n&lt;0.001\n\n\nHospital bedsize\n\n\n\n\n\n\n\n\n    Large\n—\n—\n\n\n\n\n    Medium\n-8,828\n-18,166, 511\n0.064\n\n\n    Small\n-20,751\n-29,962, -11,540\n&lt;0.001\n\n\nHospital location/teaching status\n\n\n\n\n\n\n\n\n    Rural\n—\n—\n\n\n\n\n    Urban, non-teaching\n36,234\n25,435, 47,032\n&lt;0.001\n\n\n    Urban, teaching\n42,427\n34,043, 50,812\n&lt;0.001\n\n\nCharlson comorbidity index\n2,317\n-3.4, 4,638\n0.050\n\n\nAtrial fibrillation\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n40,248\n34,475, 46,021\n&lt;0.001\n\n\nCerebrovascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n50,371\n41,561, 59,182\n&lt;0.001\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n54,384\n49,171, 59,597\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n833\n-5,885, 7,552\n0.8\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-38,631\n-45,680, -31,581\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-17,932\n-34,164, -1,699\n0.030\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-3,300\n-10,971, 4,372\n0.4\n\n\nPrior MI\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-25,594\n-30,381, -20,807\n&lt;0.001\n\n\nPrior PCI\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-30,746\n-35,178, -26,315\n&lt;0.001\n\n\n\n1\nCI = Confidence Interval"
  }
]